MedPath

Slim honey in Obesity

Not Applicable
Completed
Conditions
Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases
Registration Number
CTRI/2020/08/027196
Lead Sponsor
Royal Bee Natural Products Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

1.Male and/or female volunteers aged between 18 to 65 years both inclusive.

2.BMI ( >) greater than or equal to 25 kg/m2 and less than or equal to ( <) 34.9 Kg/m2.

3.Willing to do exercise for a span of 30 minutes daily for at least5 days in a week.

4.Willing to follow diet advised by investigator

5.Willing to come for regular follow-up visits.

Exclusion Criteria

1.Intake of over the counter weight loss agents, centrally acting appetite suppressants or prior surgery for obesity in the previous three months.

2.History of pathophysiologic/genetic syndromes associated with obesity (Cushingâ??s syndrome, Turnerâ??s syndrome, and Parder- Willi Syndrome).

3.Alcoholics and subjects with substance abuse.

4.Subject with evidence of malignancy

5.Subjects having history of underlying inflammatory arthropathy, septic arthritis, inflammatory joint disease, gout, pseudo gout, Pagetâ??s disease, joint fracture, acromegaly, fibromyalgia, rheumatoid arthritis.

6.Subjects having history of coagulopathies, cardiovascular diseases, asthma.

7.Subjects with HbAlc > 7 % and poorly controlled diabetes mellitus, poorly controlled hypertension.

8.TSH > 10 mIU/L and T3 and T4 higher than normal range.

9.Pregnant and lactating women.

10.Subjects with hepatic and renal failure.

11.Subjects on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.

12.Subjects with hypersensitivity to any one ingredient of the drugs.

13.Subjects who have participated in other trial within last 3 months.

14.Any other condition which the principal investigator thinks may jeopardize the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
change in body weight (kg)Timepoint: 6 weeks
Secondary Outcome Measures
NameTimeMethod
Change in anthropometric measurementsTimepoint: 6 weeks;Change in quality of lifeTimepoint: 6 weeks;Tolerability of drugsTimepoint: 6 weeks
© Copyright 2025. All Rights Reserved by MedPath